JAPAN’S EISAI CO. DEVELOPS NEW DRUG FOR ALZHEIMER DISEASE

Highlights – Japan’s Eisai Co. develops new drug for Alzheimer disease. The drug has been developed with U.S. firm Biogen Inc. The U.S. Food and Drug Administration on Monday approved of the new drug named ‘Aduhelm’. Aduhelm reduces amyloid beta…

Eisai Comes Into a Licensing Agreement with the Medac Regarding the Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan

Eisai Co., Ltd. announced today that it has entered into a license agreement with medac Gesellschaft fur klinische Spezialpraparate mbH for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan. Medac is marketing this product…